







an Open Access Journal by MDPI

Causes, Consequences, Challenges and Opportunities of Tumor Angiogenesis

Guest Editors:

Dr. Laura Evangelista

Department of Nuclear Medicine, Humanitas University, Pieve Emanuele, 20072 Milan, Italy

Prof. Dr. Luigi Mansi

Section Health and Development, Interuniversity Research Center for Sustainability (CIRPS), 00038 Rome, Italy

Deadline for manuscript submissions:

closed (15 December 2023)

Message from the Guest Editors

Neoangiogenesis is essential for the growth of tumors, mainly in the case of solid and undifferentiated cancers. Magnetic resonance imaging (MRI) with contrast enhancement (ce) and new radiopharmaceutical agents for PET imaging can be useful to detect and also to monitor this pathophysiological process. This Special Issue aims to:

- Define the role of MRI with ce and the role of other imaging technologies in evaluating the neoangiogenesis.
- Assess the advantages of new radiopharmaceutical agents for monitoring the evaluation of response to new targeted therapies in tumors.













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us